1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Drugs In Development, 2022, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 12, 33, 28, 5, 95, 26 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 4 molecules, respectively.
Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Chronic Obstructive Pulmonary Disease (COPD) - Overview
- Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development
- Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles
- Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects
- Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products
- Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones
- Featured News & Press Releases
- Aug 09, 2022: Dimerix announces new patent family application for DMX-700
- Aug 09, 2022: Verona Pharma to announce top-line data from Phase 3 ENHANCE-2 Trial of nebulized ensifentrine for COPD
- Aug 09, 2022: Verona Pharma announces ensifentrine meets primary endpoint in phase 3 ENHANCE-2 trial for COPD
- Jul 11, 2022: RS Biotherapeutics reports positive results from proof-of-concept trial for first investigational compound
- Jul 04, 2022: DMX-700 shows significant efficacy with 80% reduction in lung injury of COPD
- Jun 09, 2022: Verona Pharma completes enrollment in phase 3 ENHANCE-1 trial evaluating ensifentrine for maintenance treatment of COPD
- Jun 06, 2022: Verona Pharma to host KOL event on June 16, 2022
- May 23, 2022: Therapeutic Solutions International receives IND number 28508 for Chronic Obstructive Pulmonary Disease clinical trial and enters binding discussions with FDA for initiation of phase I/II Clinical Trial
- May 18, 2022: Successful completion of phase I study for lead asset EP395
- May 18, 2022: Verona Pharma to present successful TQT analysis demonstrating no clinically relevant effect on cardiac conduction at the American Thoracic Society 2022
- May 12, 2022: Phase III lung Adult Stem Cell company announces and files patent on leukine-induced myeloid derived suppressor cells and JadiCell for treatment of COPD
- May 09, 2022: Therapeutic Solutions International files Investigational New Drug application for treatment of Chronic Obstructive Pulmonary Disease (COPD) using JadiCell universal donor adult stem cells
- Mar 31, 2022: Kither Biotech announces publication of new data in Science Translational Medicine
- Mar 28, 2022: Sanofi continues on path to industry leadership in Immunology with Dupixent (dupilumab) as key driver
- Mar 21, 2022: Pulmatrix announces positive top-line data evaluating PUR1800 in Patients with Stable COPD
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, 2022
- Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, 2022
- Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AB Science SA
- AB2 Bio Ltd
- Acahealth Pharma and Biotech Co Ltd
- Aeon Respire Inc
- Afimmune Biopharma Ltd
- AIBIOS Co Ltd
- Akari Therapeutics Plc
- AlgiPharma AS
- Allinaire Therapeutics LLC
- Alveolus Bio Inc
- Amgen Inc
- Angiocrine Bioscience Inc
- Apollo Therapeutics LLC
- Aquilon Pharmaceuticals SA
- Aridis Pharmaceuticals Inc
- Arrowhead Pharmaceuticals Inc
- AstraZeneca Plc
- Atriva Therapeutics GmbH
- AusBio Ltd
- Axolo Pharma Inc
- Bai Shuo Beijing Pharmaceutical Technology Co Ltd
- Bayer AG
- BioMarck Pharmaceuticals Ltd
- Biotoxtech Co Ltd
- Boehringer Ingelheim International GmbH
- C4X Discovery Holdings Plc
- CALYXHA Biotechnologies GmbH
- Cambryn Biologics LLC
- Cantex Pharmaceuticals Inc
- Cellular Biomedicine Group Inc
- Celon Pharma SA
- Chiesi Farmaceutici SpA
- Cipla Ltd
- Circassia Group Plc
- Clarametyx Biosciences Inc
- Covenant Therapeutics LLC
- Crystec Ltd
- CSL Ltd
- Cureveda LLC
- Curovir AB
- Cytokinetics Inc
- Denovo Biopharma LLC
- Diadem Biotherapeutics Inc
- Diffusion Pharmaceuticals Inc
- Dimerix Ltd
- Domainex Ltd
- Eisai Co Ltd
- EmphyCorp Inc
- Enalare Therapeutics Inc
- Enzychem Lifesciences Corp
- EpiEndo Pharmaceuticals Ehf
- Epitracker Inc
- ethris GmbH
- Evaxion Biotech ApS
- F. Hoffmann-La Roche Ltd
- Foresee Pharmaceuticals Co Ltd
- Galephar Pharmaceutical Research Inc
- Gilead Sciences Inc
- Glenmark Pharmaceuticals Ltd
- Grifols SA
- GSK plc
- Gurus BioPharm Inc
- Hangzhou Metai Pharmaceutical Technology Co Ltd
- Haplnscience Inc
- iCeutica Inc
- Icure Pharmaceutical Inc
- Incannex Healthcare Ltd
- Inmagene Biopharmaceuticals Ltd
- InMed Pharmaceuticals Inc
- Inmunotek SL
- Insmed Inc
- InStatin Inc
- INVENT Pharmaceuticals Inc
- Invion Ltd
- Ionis Pharmaceuticals Inc
- Jiangsu Hengrui Medicine Co Ltd
- JiangSu Qyuns Therapeutics Co Ltd
- Johnson & Johnson
- Joincare Pharmaceutical Group Industry Co Ltd
- KBP Biosciences Co Ltd
- KeyMed Biosciences Inc
- Kinaset Therapeutics Inc
- Kither Biotech Srl
- Korea United Pharm Inc
- Koutif Therapeutics LLC
- Kyowa Kirin Co Ltd
- Landos Biopharma Inc
- Laurel Therapeutics
- LTT Bio-Pharma Co Ltd
- Mabwell Shanghai Bioscience Co Ltd
- Mariposa Health Ltd
- MD Healthcare Inc
- MDimune Inc
- Mereo Biopharma Group Plc
- Meridigen Biotech Co Ltd
- Metagone Biotech Inc
- MIFCOR Inc
- Modulus Discovery Inc
- Naegis Pharmaceuticals Inc
- NB Health Laboratory Co Ltd
- NeuImmune Inc
- Novabiotics Ltd
- NovaCell Technology Inc
- Novartis AG
- Nuvara Therapeutics LLC
- Omnispirant Ltd
- Orchid Pharma Ltd
- Organicell Regenerative Medicine Inc
- Orphomed Inc
- Palo BioFarma SL
- Pantherics Inc
- PharmaLundensis AB
- Pharmaxis Ltd
- Prous Institute for Biomedical Research SA
- Pulmatrix Inc
- Pulmotect Inc
- Qu Biologics Inc
- RAGE Biotech Pty Ltd
- Regeneron Pharmaceuticals Inc
- Renovion Inc
- Resolys Bio Inc
- Respiratorius AB
- Rhizen Pharmaceuticals SA
- RS BioTherapeutics Inc
- Rubedo Life Sciences Inc
- S.Biomedics Co Ltd
- San Rocco Therapeutics LLC
- Santhera Pharmaceuticals Holding AG
- Serenity Bioworks Inc
- Shanghai KE Pharmaceutical Co Ltd
- Sichuan Haisco Pharmaceutical Co Ltd
- Silurian Pharmaceuticals Inc
- Silver Valley Pharmaceutical Co Ltd
- SMSbiotech Inc
- SolAeroMed Inc
- SpliSense Ltd
- sterna biologicals Gmbh & Co KG
- Sulfateq BV
- Surrozen Inc
- Suzhou Connect Biopharmaceuticals Ltd
- Suzhou Regend Therapeutics Co Ltd
- Symmune Therapeutics LLC
- Synovo GmbH
- Syntrix Pharmaceuticals
- Taiho Pharmaceutical Co Ltd
- Tetherex Pharmaceuticals Corp
- TFF Pharmaceuticals Inc
- Therapeutic Solutions International Inc
- Theratrophix LLC
- Theravance Biopharma Inc
- Thirty Respiratory Ltd
- Torrent Pharmaceuticals Ltd
- Unity Biotechnology Inc
- Validus Cellular Therapeutics Inc
- Verona Pharma Plc
- Verra Therapeutics LLC
- Vicenna Pharmaceuticals Inc
- Vitti Labs LLC
- vTv Therapeutics Inc
- Zhengda Tianqing Pharmaceutical Group Co Ltd
